CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Sumanta K. Pal(City of Hope), Samer A. Srour(The University of Texas MD Anderson Cancer Center), Leah M. Williams, Alissa Keegan, Sebastian Klobuch(The Netherlands Cancer Institute), Changan Guo, Ben Tran(The Royal Melbourne Hospital), Sagar S. Patel(University of Utah), Phuong K. Morrow(Cornell University), Adrian G. Sacher(Princess Margaret Cancer Centre), Rachel R. Yuen, Anna Ma(Metis Design Corporation (United States)), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Luís Meza(City of Hope), Heidi Heath, Sushant Karnik, Henia Dar, Ellen B. Gurary(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael E. Hurwitz(Yale University), Lihua E. Budde(City Of Hope National Medical Center), Mary‐Lee Dequéant, Neeraj Agarwal(University of Utah), John B.A.G. Haanen(Leiden University Medical Center), Simon J. Harrison(Peter MacCallum Cancer Centre), Qiuling Ally He
Cited by 137
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
|Journal of Clinical Oncology|2013|799
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719